Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia
Abstract:Desmopressin (DDAVP) may be used to augment the action of factor VIII in mild haemophilia. Its use has been associated with serious adverse effects. We report a case of a three-year-old child with a family history of haemophilia who suffered complications due to severe acute hyponatraemia following the administration of this drug for post-tonsillectomy bleeding.
“…Thirteen publications that utilized desmopressin for AT procedures in patients with mild bleeding disorders were identified and are summarized in Table 1. This included 144 patients aged 16 months to 45 years [5,[9][10][11][12][13][14][15][16][17]. DDAVP dosing was the standard 0.3 lg kg )1 in all patients except in the first experience by Mannucci, who utilized 0.5 lg kg )1 [5].…”
Section: Resultsmentioning
confidence: 99%
“…Additional adverse events included tachyphylaxis described in one patient [11]. Antifibrinolytic agents were utilized in 72 patients (50%) [5,[9][10][11][12][13][14]16,19]. Dosing and frequency varied widely.…”
Many patients with mild inherited bleeding disorders such as von Willebrand disease (VWD), mild haemophilia A (HA) and platelet function defects (PFD) undergo adenoidectomy and/or tonsillectomy (AT) procedures each year. Management of bleeding in these patients can be challenging, as little published data exist to guide haemostatic management during these relatively common procedures. Therefore, the literature was reviewed to identify AT procedures in patients with 1-deamino-8-D-argine vasopressin responsive mild bleeding disorders. The review revealed no randomized prospective trials of haemostatic management in this patient population. Case reports and small case series identified 144 patients who had AT procedures. Frequency of desmopressin and antifibrinolytic dosing varied widely. Fifteen percentage of patients experienced postoperative bleeding with nearly half being early (<24 h) bleeding and half being late (>24 h) bleeding. Hyponatraemia complicated the procedures in 47% of cases and six hyponatremic seizures were reported. Issues identified by this review that need to be addressed in future clinical trials include type and amount of fluid restriction when utilizing desmopressin, duration of antifibrinolytic therapy and duration and frequency of desmopressin dosing.
“…Thirteen publications that utilized desmopressin for AT procedures in patients with mild bleeding disorders were identified and are summarized in Table 1. This included 144 patients aged 16 months to 45 years [5,[9][10][11][12][13][14][15][16][17]. DDAVP dosing was the standard 0.3 lg kg )1 in all patients except in the first experience by Mannucci, who utilized 0.5 lg kg )1 [5].…”
Section: Resultsmentioning
confidence: 99%
“…Additional adverse events included tachyphylaxis described in one patient [11]. Antifibrinolytic agents were utilized in 72 patients (50%) [5,[9][10][11][12][13][14]16,19]. Dosing and frequency varied widely.…”
Many patients with mild inherited bleeding disorders such as von Willebrand disease (VWD), mild haemophilia A (HA) and platelet function defects (PFD) undergo adenoidectomy and/or tonsillectomy (AT) procedures each year. Management of bleeding in these patients can be challenging, as little published data exist to guide haemostatic management during these relatively common procedures. Therefore, the literature was reviewed to identify AT procedures in patients with 1-deamino-8-D-argine vasopressin responsive mild bleeding disorders. The review revealed no randomized prospective trials of haemostatic management in this patient population. Case reports and small case series identified 144 patients who had AT procedures. Frequency of desmopressin and antifibrinolytic dosing varied widely. Fifteen percentage of patients experienced postoperative bleeding with nearly half being early (<24 h) bleeding and half being late (>24 h) bleeding. Hyponatraemia complicated the procedures in 47% of cases and six hyponatremic seizures were reported. Issues identified by this review that need to be addressed in future clinical trials include type and amount of fluid restriction when utilizing desmopressin, duration of antifibrinolytic therapy and duration and frequency of desmopressin dosing.
“…A total of 20 patients (28%) had documented concomitant disorders (table 2). 4,6,7,17,19,21,23,25 In addition to desmopressin, 24 patients received at least 1 concomitant medication (table 3). 2, 3, 6, 9, 11, 19 -22, 25 Symptoms.…”
Section: Resultsmentioning
confidence: 99%
“…The fact that almost a third (28%) of patients suffered from concomitant disorders should lead to the careful use of desmopressin. 4,6,7,17,19,21,23,25 When a clear link to water homeostasis can be established (eg diarrhea) desmopressin should be used with extreme caution.…”
Based on this analysis, we conclude that the use of desmopressin should be cautiously considered, careful monitoring should be performed during the initiation of therapy, and particular care should be taken when treating young children and when prodromal symptoms such as nausea, vomiting and headaches occur.
“…More serious side-effects include fluid retention, hyponatremia and seizures. 36 It has been suggested that desmopressin is dangerous in children under 18 months old 37 as there is increased risk of cerebral irritation. However, Revel-Vilk et al 30 would advocate the use of desmopressin in this age group where there is a reasonable chance of benefit and that fluid intake be minimized.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.